Space health nonprofit to send 6 more experiments to space on Houston company's next mission

medicine in orbit

TRISH is sending six research projects onboard Axiom Space's next mission, which is expected to launch in January. Photo via bcm.com

A Houston organization announced that it plans to launch six more experiments into space next year that look to learn more about everything from motion sickness to genome alterations during space travel.

The Translational Research Institute for Space Health, or TRISH, which is part of BCM’s Center for Space Medicine, will team up once more with Houston-based Axiom Space on its third private astronaut mission to the International Space Station, Ax-3, which is expected to launch in January. TRISH also sent experiments on Axiom's Ax-2 mission that launched in May.

The experiments are part of TRISH's Enhancing eXploration Platforms and Analog Definition (EXPAND) program, which aims "to help humans thrive on future space missions," according to a release.

“Our commercial spaceflight partners such as Axiom Space are instrumental to cutting-edge research, including these projects designed to reveal how the human body and mind function in the extreme environment of space,” Dr. Emmanuel Urquieta, TRISH chief medical officer, EXPAND program lead and assistant professor in the Center for Space Medicine at Baylor. “This work represents an important step in our journey to understand the body's response to challenging conditions, which is critical for improving human health both here on Earth and on future long-duration missions, including to the Moon and Mars.”

The six project onboard Ax-3 include:

Cognitive and Physiologic Responses in Commercial Space Crew on Short-Duration Missions, Mathias Basner, M.D., Ph.D., M.S., University of Pennsylvania Perelman School of Medicine: Basner’s team will track spaceflight participants’ memory, abstraction, spatial orientation, emotion recognition, risk decision-making and sustained attention before and after space travel
Otolith and Posture Evaluation II, Mark Shelhamer, Sc.D., Johns Hopkins University: Shelhamer's team will study how inner ears and eyes sense and respond to motion before and immediately after spaceflight to predict who is likely to develop space motion sickness.
Space Omics + BioBank, Richard Gibbs, Ph.D., Baylor College of Medicine: Gibbs’ team will gather biological specimens from astronauts before and after their mission to assess the effects of spaceflight on the human body at the genomic level.
SANS Surveillance, TRISH: The institute will study Spaceflight Associated Neuro-Ocular Syndrome by collecting vision function data during the ground phases of the mission.
Standardized research questionnaires, TRISH: The institute will gather contextual and qualitative data points for its EXPAND research database related to sleep, personality, health history, team dynamics and immune-related symptoms.
Sensorimotor adaptation, TRISH: The institute will collect data on how spaceflight participants' ability to stand, balance and have full body control.

Ax-3 is Axiom's third commercial astronaut mission to the ISS, which the company announced in March. The crew, which includes Commander Michael López-Alegría, Pilot Walter Villadei, and Mission Specialists Alper Gezeravcı and Marcus Wandt, will spend 14 days on the ISS. The mission will launch from NASA’s Kennedy Space Center in Florida aboard a SpaceX Dragon spacecraft.

Axiom also has plans for its fourth private mission, Ax-4, which it announced in August.

In addition to the partnership with Axiom, TRISH also announced late last month that it has made a new agreement with the Australian Antarctic Division's Polar Medicine Unit. The collaboration will nominate pilot projects that focus on challenges associated with extreme isolation, which have applications in long-duration space travel to the Moon and Mars.

“Our international collaboration with the AAD will extract insights to benefit all future astronauts, as well as other explorers of extreme environments,” said Dr. Dorit Donoviel, associate professor in the Center for Space Medicine at Baylor and TRISH executive director. “This agreement marks the beginning of yet another exciting venture into space health research for TRISH, and we look forward to collaborating with the AAD to advance our shared goal of promoting safe human exploration.”

In March, TRISH also announced an international agreement with the Korea National Institute of Health. The two organizations plan to collaborate on research related to mental health issues due to space travel, the challenges of food supply in deep space, the negative effects of space radiation and en-suite medical care for long-duration space travel.

TRISH is also slated to launch nine experiments on board SpaceX's Polaris Dawn mission, which is now expected to launch no earlier than 2024. The research aboard Polaris Dawn is intended to complement research supported by TRISH on the Inspiration4 all-civilian mission to orbit.

From Your Site Articles

Emmanuel Urquieta, chief medical officer of TRISH, joins the Houston Innovators Podcast. Photo via LinkedIn

Houston innovator on the importance of commercial missions for the future of space health research

HOUSTON INNOVATORS PODCAST EPISODE 189

With the rise of commercial space flight, researchers have increased access to space health data that's key to the future of the industry as a whole. The organization that's conducting this valuable research is based right in Houston's Texas Medical Center.

TRISH, or the Translational Research Institute for Space Health, is an organization based out of Baylor College of Medicine and partnered with NASA's Human Spaceflight group. As commercial space companies have emerged, TRISH has strategically aligned with these businesses to bring back health data from the civilian trips.

“Most of the research that’s done at NASA and other government agencies usually takes decades to get something that could be implemented in space or terrestrially," Dr. Emmanuel Urquieta, chief medical officer for TRISH, says on the Houston Innovators Podcast. "What we do at TRISH is something different.

"On the one hand, we look at really new technologies that are just an idea, but could be really game changing," he continues. "Then on the other hand, we look at technologies already in the market that could be tweaked to work in spaceflight.”

Since 2021, TRISH has conducted its research on four missions — Inspiration4, the first all-civilian mission to space; Axiom Mission 1, the first all civilian mission to the International Space Station; MS20, which flew two Japanese civilians to ISS; and, most recently, Axiom Mission 2, which included the first all-private crew commanded by a woman and two members of the Kingdom of Saudi Arabia's national astronaut program.

“We really saw the value of implementing research in civilians because they are different from your traditional government astronaut,” Urquieta says. “In civilians, you see a more diverse population.”

Urquieta says TRISH's experiments on these missions all fall within a few pillars of space health, including space's effects on sensory motor skills, like balance and motion sickness, as well as mental health, environmental data from the vehicles, vital monitoring, and more.

“We’ve developed a capability to collect high-priority, high-value data from these space flight participants without having to train them for long periods of time — which is a challenge, because they don’t train for years like traditional astronauts,” he explains.

The plan, Urquieta says, is to be able to share TRISH's space health data in order to more safely send humans into space. He shares more about TRISH's program and the challenges the organization faces on the show. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-area lab grows with focus on mobile diagnostics and predictive medicine

mobile medicine

When it comes to healthcare, access can be a matter of life and death. And for patients in skilled nursing facilities, assisted living or even their own homes, the ability to get timely diagnostic testing is not just a convenience, it’s a necessity.

That’s the problem Principle Health Systems (PHS) set out to solve.

Founded in 2016 in Clear Lake, Texas, PHS began as a conventional laboratory but quickly pivoted to mobile diagnostics, offering everything from core blood work and genetic testing to advanced imaging like ultrasounds, echocardiograms, and X-rays.

“We were approached by a group in a local skilled nursing facility to provide services, and we determined pretty quickly there was a massive need in this area,” says James Dieter, founder, chairman and CEO of PHS. “Turnaround time is imperative. These facilities have an incredibly sick population, and of course, they lack mobility to get the care that they need.”

What makes PHS unique is not only what they do, but where they do it. While they operate one of the largest labs serving skilled nursing facilities in the state, their mobile teams go wherever patients are, whether that’s a nursing home, a private residence or even a correctional facility.

Diagnostics, Dieter says, are at the heart of medical decision-making.

“Seventy to 80 percent of all medical decisions are made from diagnostic results in lab and imaging,” he says. “The diagnostic drives the doctor’s or the provider’s next move. When we recognized a massive slowdown in lab results, we had to innovate to do it faster.”

Innovation at PHS isn’t just about speed; it’s about accessibility and precision.

Chris Light, COO, explains: “For stat testing, we use bedside point-of-care instruments. Our phlebotomists take those into the facilities, test at the bedside, and get results within minutes, rather than waiting days for results to come back from a core lab.”

Scaling a mobile operation across multiple states isn’t simple, but PHS has expanded into nine states, including Texas, Oklahoma, Kansas, Missouri and Arizona. Their model relies on licensed mobile phlebotomists, X-ray technologists and sonographers, all trained to provide high-level care outside traditional hospital settings.

The financial impact for patients is significant. Instead of ambulance rides and ER visits costing thousands, PHS services often cost just a fraction, sometimes only tens or hundreds of dollars.

“Traditionally, without mobile diagnostics, the patient would be loaded into a transportation vehicle, typically an ambulance, and taken to a hospital,” Dieter says. “Our approach is a fraction of the cost but brings care directly to the patients.”

The company has also embraced predictive and personalized medicine, offering genetic tests that guide medication decisions and laboratory tests that predict cognitive decline from conditions like Alzheimer's and Parkinson’s.

“We actively look for complementary services to improve patient outcomes,” Dieter says. “Precision medicine and predictive testing have been a great value-add for our providers.”

Looking to the future, PHS sees mobile healthcare as part of a larger trend toward home-based care.

“There’s an aging population that still lives at home with caretakers,” Dieter explains. “We go into the home every day, whether it’s an apartment, a standalone home, or assisted living. The goal is to meet patients where they are and reduce the need for hospitalization.”

Light highlighted another layer of innovation: predictive guidance.

“We host a lot of data, and labs and imaging drive most treatment decisions,” Light says. “We’re exploring how to deploy diagnostics immediately based on results, eliminating hours of delay and keeping patients healthier longer.”

Ultimately, innovation at PHS isn’t just about technology; it’s about equity.

“There’s an 11-year life expectancy gap between major metro areas and rural Texas,” Dieter says. “Our innovation has been leveling the field, so everyone has access to high-quality diagnostics and care, regardless of where they live.”

Aegis Aerospace appoints Houston space leader as new president

moving up

Houston-based Aegis Aerospace's current chief strategy officer, Matt Ondler, will take on the additional role of president on Jan. 1. Ondler will succeed Bill Hollister, who is retiring.

“Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers,” Stephanie Murphy, CEO of Aegis Aerospace, said in a news release.

Hollister guided Aegis Aerospace through expansion and innovation in his three years as president, and will continue to serve in the role of chief technology officer (CTO) for six months and focus on the company's technical and intellectual property frameworks.

"Bill has played an instrumental role in shaping the success and growth of our company, and his contributions leave an indelible mark on both our culture and our achievements," Murphy said in a news release.

Ondler has a background in space hardware development and strategic leadership in government and commercial sectors. Ondler founded subsea robots and software company Houston Mechatronics, Inc., now known as Nauticus Robotics, and also served as president, CTO and CSO during a five-year tenure at Axiom Space. He held various roles in his 25 years at NASA and was also named to the Texas Aerospace Research and Space Economy Consortium Executive Committee last year.

"I am confident that with Matt at the helm as president and Bill supporting us as CTO, we will continue to build on our strong foundation and further elevate our impact in the space industry," Murphy said in a news release. "Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers."

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME